TrialDrug design, development and therapy2018

Comparison of efficacy and safety between two different irbesartan, generic vs branded, in the treatment of Korean patients with mild-to-moderate hypertension: an 8-week, multicenter, randomized, open-label, Phase IV clinical study.

Seung Hwan Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.